• γδ T cells;
  • BCG;
  • C8/119S;
  • Der f 2;
  • Th1/Th2


Background γδ T cells have been described as one of immune regulators in patients with infection, malignancy, and allergy.

Objective To elucidate the ability of γδ T cells as an allergen immunotherapy candidate, the effectiveness of human γδ T cells in allergen-specific T-helper type 2 (Th2)-type T cells was evaluated in vitro.

Methods House dust mite-specific Th2-type T cell clones, Bacillus Calmette–Guerin (BCG)-specific Th1-type T cell clones, and γδ T cell lines were established from the peripheral blood mononuclear cells of two patients with allergic rhinitis. The effectiveness of γδ T cells and BCG-specific Th1-type T cell clones in the modulation of allergen-specific Th2 cells in terms of their cytokine productions was evaluated.

Results In response to cognate antigens, the γδ T cell lines demonstrated a proliferation and production of IFN-γ that exceeded that of BCG-specific Th1-type T cell clones (mean stimulation index: 14.5 vs. 2.8, mean IFN-γ: 130.5 vs. 10.0 pg/mL). When the γδ T cell lines and mite-allergen-specific Th2 clones were co-cultured with each other, only the levels of IL-4 (mean, −87%) decreased, but not the levels of IL-5 and IL-13, with an increasing concentration of γδ T cell antigen and IFN-γ production (mean, +730%).

Conclusion These results demonstrated that γδ T cells derived from allergic patients might thus have a partial ability to modulate allergen-specific Th2-skewed immunity.